| Not Yet Recruiting | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) NCT07166549 | University Hospital, Basel, Switzerland | Phase 1 |
| Not Yet Recruiting | A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) NCT07101328 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NCT07516093 | Nurix Therapeutics, Inc. | Phase 3 |
| Not Yet Recruiting | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006 | Nurix Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Anti CD19 Gene Therapy for B-cell Lymphoma NCT07211048 | Anhui Provincial Hospital | N/A |
| Enrolling By Invitation | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials NCT07474051 | AvenCell Therapeutics, Inc. | — |
| Recruiting | Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B- NCT07369492 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy o NCT07162571 | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma NCT07270835 | The First Affiliated Hospital of Soochow University | Phase 4 |
| Not Yet Recruiting | Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients NCT07198373 | Beijing GoBroad Hospital | — |
| Active Not Recruiting | Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers NCT07162181 | Eli Lilly and Company | Phase 2 |
| Not Yet Recruiting | CD30 CAR-T in the Treatment of CD30 Positive Lymphoma NCT07048353 | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | EARLY_Phase 1 |
| Recruiting | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma NCT07009002 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Withdrawn | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma NCT06670105 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors NCT06976437 | YANRU WANG | EARLY_Phase 1 |
| Recruiting | Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma NCT06987916 | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 1 / Phase 2 |
| Active Not Recruiting | Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. NCT07101913 | Hospices Civils de Lyon | — |
| Recruiting | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zan NCT06742996 | BeOne Medicines | Phase 3 |
| Recruiting | Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma NCT07093073 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 |
| Recruiting | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies NCT06758713 | The Third Affiliated Hospital of Southern Medical University | Phase 1 |
| Recruiting | A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies NCT06820268 | NovaOnco Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Active Not Recruiting | Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Wit NCT06744075 | Centre Henri Becquerel | N/A |
| Recruiting | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants NCT06634589 | BeOne Medicines | Phase 1 / Phase 2 |
| Recruiting | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920 | Rita Assi | Phase 2 |
| Recruiting | Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma NCT07093086 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 |
| Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for t NCT06566586 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors NCT06662227 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Terminated | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas NCT06248086 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignanc NCT06492304 | CRISPR Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma NCT06485076 | University Health Network, Toronto | N/A |
| Recruiting | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients W NCT06213311 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) NCT06002659 | Uppsala University | Phase 1 / Phase 2 |
| Recruiting | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas NCT06350318 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Ly NCT06058858 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage NCT05731375 | UMC Utrecht | — |
| Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma NCT06180174 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma NCT06415708 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Unknown | Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibito NCT05495828 | Peking University People's Hospital | — |
| Recruiting | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas NCT05934838 | Weill Medical College of Cornell University | Phase 1 |
| Withdrawn | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before NCT05929716 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas NCT05365659 | Iksuda Therapeutics Ltd. | Phase 1 |
| Unknown | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies NCT05932173 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Recruiting | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NCT05615636 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies NCT05739227 | Xuzhou Medical University | EARLY_Phase 1 |
| Active Not Recruiting | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma NCT05757700 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell NCT05270057 | Medical College of Wisconsin | Phase 1 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma NCT05590221 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma NCT05412290 | Washington University School of Medicine | Phase 1 |
| Unknown | ThisCART19A for B-NHL Relapsed After Auto-CAR T NCT05691153 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Unknown | Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma NCT05755828 | The Affiliated Hospital of Xuzhou Medical University | Phase 2 |
| Terminated | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT05611853 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Recruiting | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphod NCT05092451 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies NCT05487651 | Athenex, Inc. | Phase 1 |
| Withdrawn | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies NCT05570188 | Kunming Hope of Health Hospital | Phase 1 / Phase 2 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas NCT05415098 | Ascentage Pharma Group Inc. | Phase 1 |
| Recruiting | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502 | Brown University | Phase 2 |
| Unknown | Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion NCT05385263 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Unknown | Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART NCT05286164 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Recruiting | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemi NCT06081478 | Beijing Tongren Hospital | Phase 2 |
| Unknown | A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas NCT05113069 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies NCT04599634 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Natural Killer (NK) Cell Therapy for B-Cell Malignancies NCT05379647 | Zhejiang University | Phase 1 |
| Active Not Recruiting | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers NCT05024045 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | Venetoclax Plus Inotuzumab for B-ALL NCT05016947 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma NCT05014100 | Puyang Oilfield General Hospital | Phase 2 |
| Withdrawn | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies NCT05015972 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | EARLY_Phase 1 |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Recruiting | A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma NCT04993690 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Unknown | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma NCT04782193 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Withdrawn | CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL NCT04877080 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 |
| Terminated | Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets i NCT04804254 | AbbVie | Phase 1 |
| Unknown | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors NCT04814004 | Kai Lin Xu; Jun Nian Zheng | Phase 1 |
| Unknown | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignanci NCT04796688 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Unknown | Induced-T Cell Like NK Cells for B Cell Malignancies NCT04747093 | Nanfang Hospital, Southern Medical University | Phase 1 / Phase 2 |
| Withdrawn | Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma NCT04641806 | Versailles Hospital | — |
| Unknown | Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA NCT04539119 | Ruijin Hospital | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 NCT04418141 | Curon Biopharmaceutical (Australia) Co Pty Ltd | Phase 1 |
| Completed | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus NCT04313608 | Hoffmann-La Roche | Phase 1 |
| Completed | CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies NCT04605666 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Unknown | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies NCT04264039 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Unknown | Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acut NCT04289220 | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| Completed | PD1-CD19-CART in Patients With r/r B-cell Lymphoma NCT04213469 | Bioray Laboratories | N/A |
| Completed | CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients NCT04260932 | Hebei Yanda Ludaopei Hospital | Phase 1 |
| Active Not Recruiting | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies NCT04088864 | Stanford University | Phase 1 |
| Active Not Recruiting | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy NCT04148430 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | FT516 in Subjects With Advanced Hematologic Malignancies NCT04023071 | Fate Therapeutics | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma NCT03995147 | University of Chicago | Phase 2 |
| Completed | A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy NCT04036019 | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 1 |
| Unknown | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies NCT04007978 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Ac NCT04045028 | Genentech, Inc. | Phase 1 |
| Terminated | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CAR NCT04035434 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Unknown | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malign NCT04008251 | Wuhan Sian Medical Technology Co., Ltd | Phase 1 |
| Unknown | Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphom NCT03929107 | Wenbin Qian | Phase 2 |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | Study of TG-1801 in Subjects With B-Cell Lymphoma NCT03804996 | TG Therapeutics, Inc. | Phase 1 |
| Unknown | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies NCT03881774 | Henan Cancer Hospital | Phase 1 |
| Completed | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants Wit NCT03761056 | Kite, A Gilead Company | Phase 2 |
| Recruiting | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patien NCT03787056 | Hospices Civils de Lyon | N/A |
| Unknown | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies NCT03999697 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Terminated | A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Pat NCT03670888 | JHL Biotech, Inc. | Phase 1 |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Active Not Recruiting | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma NCT03478514 | Alliance Foundation Trials, LLC. | Phase 2 |
| Unknown | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies NCT04156178 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Unknown | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia NCT03854994 | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| Completed | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previo NCT03424122 | Incyte Corporation | Phase 1 |
| Unknown | CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies NCT03559439 | Shanghai Tong Ren Hospital | Phase 1 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincri NCT03467373 | Hoffmann-La Roche | Phase 1 |
| Completed | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT03424603 | Sutro Biopharma, Inc. | Phase 1 |
| Unknown | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies NCT04156243 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Unknown | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy fo NCT03398967 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Withdrawn | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies NCT03098355 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Unknown | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tu NCT03302403 | Kang YU | N/A |
| Completed | A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma NCT03307746 | University Hospital Southampton NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Unknown | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Ly NCT03281551 | Pinze Lifetechnology Co. Ltd. | Phase 1 |
| Completed | CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy NCT03068416 | Uppsala University | Phase 2 |
| Unknown | Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma NCT03258047 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Completed | A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma NCT03003039 | Nanjing Yoko Biomedical Co., Ltd. | Phase 1 |
| Unknown | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma NCT03166878 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. NCT03146533 | Shenzhen Second People's Hospital | Phase 1 / Phase 2 |
| Unknown | A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL NCT03060850 | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Phase 1 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Unknown | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia NCT03383952 | Immune Cell, Inc. | Phase 1 |
| Terminated | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma NCT02898259 | Brian Hill | Phase 1 / Phase 2 |
| Completed | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal An NCT02945215 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia NCT02933320 | Cancer Research UK | Phase 1 / Phase 2 |
| Completed | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAO NCT02741388 | The Lymphoma Academic Research Organisation | Phase 1 |
| Completed | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas NCT02900716 | Zhejiang DTRM Biopharma | Phase 1 |
| Unknown | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma NCT03101709 | Henan Cancer Hospital | Phase 1 |
| Completed | A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma NCT03189524 | BeiGene | Phase 1 |
| Unknown | Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma NCT02842138 | Peking University | Phase 1 |
| Unknown | CAR T Cells for Refractory B Cell Malignancy NCT02963038 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 / Phase 2 |
| Unknown | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies NCT03366324 | Wuhan Sian Medical Technology Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies NCT03366350 | Wuhan Sian Medical Technology Co., Ltd | Phase 1 / Phase 2 |
| Unknown | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies NCT02965092 | Wuhan Sian Medical Technology Co., Ltd | Phase 1 / Phase 2 |
| Withdrawn | CD19-targeting CAR T Cells for B Cell Lymphoma NCT02547948 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Completed | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas NCT02395601 | Constellation Pharmaceuticals | Phase 1 |
| Unknown | An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in NCT02354846 | Yonsei University | — |
| Completed | Detection and Characterization of Residual Masses in Lymphomas NCT02300402 | The Lymphoma Academic Research Organisation | — |
| Terminated | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell L NCT02266147 | Dynavax Technologies Corporation | Phase 1 / Phase 2 |
| Terminated | Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas NCT02055924 | The Lymphoma Academic Research Organisation | Phase 1 |
| Completed | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. NCT02132624 | Uppsala University | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma NCT01980654 | Pharmacyclics LLC. | Phase 2 |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma NCT01980628 | Pharmacyclics LLC. | Phase 2 |
| Completed | Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas NCT01788189 | University Hospital, Essen | Phase 1 / Phase 2 |
| Unknown | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or NCT01799083 | Han weidong | Phase 1 / Phase 2 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma NCT01593696 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Ly NCT01626495 | University of Pennsylvania | Phase 1 / Phase 2 |
| Completed | CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies NCT00968760 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lym NCT01284192 | Astellas Pharma Inc | Phase 1 |
| Completed | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myelom NCT01148108 | Telik | Phase 2 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Withdrawn | Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue NCT01044004 | Washington University School of Medicine | N/A |
| Completed | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants Wit NCT01459653 | Sandoz | — |
| Terminated | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituxima NCT00946023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas NCT00895661 | Massachusetts General Hospital | Phase 2 |
| Terminated | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma NCT00880867 | Nevada Cancer Institute | Phase 1 |
| Completed | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma NCT00849654 | Pharmacyclics LLC. | Phase 1 |
| Active Not Recruiting | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL NCT00586391 | Baylor College of Medicine | Phase 1 |
| Completed | A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT00741871 | S*BIO | Phase 1 |
| Terminated | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma NCT00788606 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Ly NCT00761384 | Lund University Hospital | Phase 1 / Phase 2 |
| Completed | A Study for Patients With Non-Hodgkin's Lymphomas NCT00542919 | Eli Lilly and Company | Phase 2 |
| Terminated | Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma NCT00906841 | French Innovative Leukemia Organisation | Phase 2 |
| Terminated | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxyd NCT00486759 | Hoffmann-La Roche | Phase 3 |
| Completed | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Mal NCT00481871 | Acrotech Biopharma Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide NCT01300793 | University of California, San Francisco | Phase 1 |
| Completed | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous T NCT00434629 | University of Pennsylvania | Phase 1 |
| Completed | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With N NCT00299494 | Pfizer | Phase 1 / Phase 2 |
| Completed | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma NCT00316511 | Agenus Inc. | Phase 1 |
| Completed | Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B NCT00338494 | Yale University | Phase 1 |
| Completed | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma ( NCT00097929 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Treatment of Aggressive Localized Lymphoma NCT00841945 | French Innovative Leukemia Organisation | Phase 3 |
| Completed | Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma NCT00138086 | Lymphoma Study Association | Phase 2 |
| Completed | Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma NCT00169468 | Lymphoma Study Association | Phase 2 |
| Completed | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma NCT00085696 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease NCT00209014 | Emory University | Phase 2 |
| Completed | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma NCT00054665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma NCT00965289 | Nantes University Hospital | Phase 2 |
| Completed | Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System NCT00001582 | National Cancer Institute (NCI) | — |
| Completed | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype NCT00001572 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vacc NCT00001512 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Treatment of Mature B-cell Lymphoma/Leukaemia NCT00162656 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lympho NCT00001271 | National Cancer Institute (NCI) | Phase 1 |